Patients with oHCM experience significant variation in cardiovascular events, health care resource use, and costs across age, sex, race, and US region.

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carolyn Ho, MD: ...

Hypertrophic cardiomyopathy (HCM) is a genetic condition that involves abnormal thickening of the heart muscle, which can increase the risk of other heart conditions. But if you have HCM, you can make ...

Please provide your email address to receive an email when new articles are posted on . Hypertrophic cardiomyopathy is the most common monogenic CV disorder, yet perhaps the most frequently ...

Treatment with aficamten significantly improved exercise capacity compared with placebo. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for aficamten for ...

Introduction The clinical management of Obstructive Hypertrophic Cardiomyopathy remains challenging, and the phase III EXPLORER-HCM trial has demonstrated that the novel cardiac myosin inhibitor ...

"Older patients often tolerate medications poorly and younger patients may feel lethargic and tired with beta blockers and calcium channel blockers. These patients would be appropriate candidates for ...

MYQORZO was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms, and by the China National Medical ...

In a move greatly welcomed by heart charities, the National Institute for Health and Care Excellence (NICE) has approved mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy ...

Please provide your email address to receive an email when new articles are posted on . Hypertrophic cardiomyopathy is the most common genetic heart disease, with prevalence estimates from one in 200 ...

Obstructive hypertrophic cardiomyopathy comes with symptoms such as shortness of breath, fatigue, and palpitations. These tips can help you manage it.

Cytokinetics, Incorporated announced five presentations related to aficamten at the upcoming European Society of Cardiology Congress 2025 in Madrid, highlighting positive topline results from the ...